News | December 17, 2025
Glenmark secures exclusive multi-regional rights to Aumolertinib from Hansoh Pharma
Hansoh Pharma will receive an upfront payment in the low double-digit millions
Hansoh Pharma will receive an upfront payment in the low double-digit millions
Glenmark's Leucovorin Calcium for Injection USP, 350 mg/vial Single-Dose Vial is bioequivalent and therapeutically equivalent to the reference listed drug
The positive outcome clears the way for Glenmark to resume commercial manufacturing at the site
Clinical studies conducted in India demonstrated that this nebulized triple therapy rapidly improves lung function and offers better control of breathlessness
Winlevi is authorized in EU for the treatment of acne vulgaris
EBITDA was Rs. 2,359.6 crore in the quarter ended September 30, 2025
The approval granted with zero supplementation requests is an important milestone in Glenmark’s respiratory pipeline
Glenmark will begin distribution in November 2025
Glenmark’s Ropivacaine Hydrochloride Injection USP is bioequivalent and therapeutically equivalent to the reference listed drug Naropin Injection of Fresenius Kabi USA
Hengrui is eligible to receive regulatory and commercial milestone payments of up to US$1.093 billion
Subscribe To Our Newsletter & Stay Updated
